Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets
Advertisement

Related Content

A Closer Look: Dr. Reddy’s Sees Global Leadership In Biosimilars Via Merck Serono Deal
Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More
India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie
Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs
Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
GSK In Pact With India’s Dr Reddy’s; Digs Deeper Into Emerging Generic Drugs Market
Advertisement
UsernamePublicRestriction

Register

SC070649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel